[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chungnam National University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":179},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,78,105,129,153],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100571776","tapering-heart-failure-medication-in-patients-with-heart-failure-with-recovered-ejection-fraction-open-label-prospective-random-trial-100571776",false,"NCT06724653","Tapering Heart Failure Medication in Patients With Heart Failure With Recovered Ejection Fraction; Open Label Prospective Random Trial","HFrecEF","Inclusion Criteria:\n\n* initial echocardiogram ejection fraction less than 40%\n* follow up echocardiogram ejection fraction over 50% and LVEDD index normal range\n* NTprobnp criteria\n\n  1. eGFR ≥60 ; less 440\n  2. eGFR 45-59: less 980\n  3. eGFR 30-44; less 1220\n  4. eGFR \\\u003C 30 : less 5300\n  5. in HD; no criteria for NTproBNP\n* on more than 3 heart failure medication ( RAS blocker, beta blocker, mineral corticoid receptor antagonist, SGLT 2 inhibitor)\n\nExclusion Criteria:\n\n1. under age 18 year\n2. uncontrolled BP ( over 150\u002F90)\n3. coronary revascularization within 6 months\n4. significant valve disease\n5. arrhythmia requiring rate control\n6. CKD with albuminuria ( over 30mg\u002Fg)\n7. Pregnancy","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"NA","Study start date is on Nov 27th 2024.\n\nA patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.",[26,27,28],"Heart Failure","Ejection Fraction","Recovery of Function",[30,31],"heart failure with recovered ejection fraction","Tapering","RECRUITING","2026-03-23",{"date":35,"type":36},"2026-03-27","ACTUAL",{"date":38,"type":36},"2025-03-06",{"date":40,"type":20},"2027-11-26",{"name":42,"class":43},"Chungnam National University Hospital","OTHER",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100555982","liver-gut-axis-study-through-identification-of-liver-disease-specific-microbiome-100555982","NCT06519162","Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome","Exploration of Liver-gut Axis Through Identification of Liver Disease-specific Microbiome","LGAS","Inclusion Criteria:\n\n* Adults aged 19 years and older diagnosed with autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic fatty liver disease, or liver abscess, who have consented to participate in this study at Chungnam National University Hospital.\n* Adults aged 19 years and older, who are cohabitants of patients diagnosed with autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic fatty liver disease, or liver abscess, and have consented to participate in this study at Chungnam National University Hospital.\n\nB. Exclusion\n\nExclusion Criteria:\n\n* Individuals under the age of 19.\n* Patients or guardians who do not consent to participate in the study",true,"19 Years",{"count":56,"type":20},3000,"OBSERVATIONAL","In this study, we aim to identify gut microbiomes specific to patients with chronic refractory liver disease and to conduct a gut-liver axis study on the pathogenesis and disease progression.",[60,61,62,63,64],"Autoimmune Hepatitis","Primary Sclerosing Cholangitis","Non-Alcoholic Fatty Liver Disease","Liver Abscess","Primary Biliary Cirrhosis",[66,67,68],"Liver Diseases","Microbiota","Immune System","2026-03-19",{"date":71,"type":36},"2026-03-20",{"date":73,"type":36},"2024-07-08",{"date":75,"type":20},"2029-07-08",{"name":42,"class":43},1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":77},"100507188","effect-of-essential-aminoacid-supplementation-and-exercise-on-skeletal-muscle-function-in-hemodialysis-patients-100507188","NCT05884138","Effect of Essential Aminoacid Supplementation and Exercise on Skeletal Muscle Function in Hemodialysis Patients","A Randomized Controlled Trial to Analyze the Effects of Essential Aminoacid Supplementation and Exercise on the Improvement of Skeletal Muscle Function in Hemodialysis Patients","Inclusion Criteria:\n\n* Patients with hemodialysis\n* Community-dwellers\n* Able to walk with or without assistive devices for more than 100 meters\n\nExclusion Criteria:\n\n* A person with cancer disease.\n* People with psychiatric symptoms.\n* A person who has an absorption disorder or has a history of resection of the small intestine or colon\n* Pregnant women\n* A person treated for acute bacterial infections\n* A person who is in a wheelchair due to inconvenience in walking.","20 Years","80 Years",{"count":88,"type":20},40,[23],"Sarcopenia can be easily observed in patients with hemodialysis. However, there were few studies on the precise concept and diagnostic criteria for sarcopenia in patients with hemodialysis. The investigators have already recognized the sarcopenia-associated mortality and morbidity in patients with hemodialysis. However, intervention studies on hemodialysis patients with sarcopenia have not been conducted until now. In 2021, the investigators conducted a pilot study to evaluate the effectiveness of the combined exercise and nutrition intervention for sarcopenia in patients with hemodialysis to confirm the effectiveness. This study is a follow-up study, conducted as a randomized controlled trial.",[92],"Sarcopenia",[94,95,96],"hemodialysis","nutrition","exercise","2026-03-17",{"date":99,"type":36},"2026-03-18",{"date":101,"type":36},"2023-08-28",{"date":103,"type":20},"2026-08-23",{"name":42,"class":43},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":115,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":77},"100453082","phase-2-adjuvant-mfolfirinox-for-high-risk-stage-iii-colon-cancer-100453082","NCT05179889","Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer","mFOLFIRINOX Versus mFOLFOX 6 as Adjuvant Treatment for High Risk Stage III (pT4N1\u002F2 or pTanyN2) Colon Cancer: Multicenter, Open Labeled, Randomized, Phase II Study","Inclusion Criteria:\n\n1. Age of 20-70 years with an ECOG ≤ 2\n2. Age of 71-75 years with an ECOG = 0\n3. Pathologically confirmed high-risk stage III colon adenocarcinoma (pT4N1 or pTanyN2)\n4. Curative radical resection (successful R0 resection) within 60 days before randomization\n5. Adequate organ functions\n\n   * ANC ≥ 2×106 cells\u002FmL\n   * Hemoglobin ≥ 9.0 g\u002FdL\n   * Platelets ≥ 100×106 cells\u002FmL\n   * Alanine aminotransferase\u002Faspartate aminotransferase ≤2.5 × times the upper limit of normal (ULN)\n   * Serum total bilirubin ≤ 1.5 ULN\n   * Alkaline phosphatase ≤ 2.5 × ULN\n   * Serum creatinine ≤1.5 × ULN or creatinine clearance \\> 50 mL\u002Fmin (Cockcroft-Gault formula)\n6. Able to understand and willing to sign and date written voluntary informed consent form\n7. Life expectancy ≥ 5 years\n\nExclusion Criteria:\n\n1. Distant metastasis\n2. Middle or lower rectal cancer of need for radiotherapy\n3. Postoperative complication of 3 or more grades of Clavien-Dindo classification\n4. Underlying disease or postoperative condition which is contraindication for chemotherapy\n5. Known hypersensitivity reaction to any study treatment component\n6. Familial adenomatosis polyposis or hereditary non-polyposis colorectal cancer\n7. Inflammatory bowel disease\n8. Previous other malignancy which cannot be curatively treated\n9. Pregnancy or breast feeding\n10. Any other situation would exclude the patient from study based on the investigator's opinion","75 Years",{"count":114,"type":20},308,[116,117],"PHASE2","PHASE3","A multicenter, open labeled randomized, phase II trial comparing mFOLFIRINOX and mFOLFOX6 as adjuvant treatment for high risk stage III (pT4N1\u002F2 or pTanyN2) colon cancer",[120],"Colon Cancer Stage III",[122],"High risk stage III (pT4N1\u002F2 or pTanyN2) colon cancer",{"date":69,"type":36},{"date":125,"type":36},"2021-07-06",{"date":127,"type":20},"2031-03-15",{"name":42,"class":43},{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":137,"targetDuration":139,"studyType":57,"phases":4,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":77},"100629955","molecular-insights-into-post-cardiac-arrest-brain-injury-via-csf-multi-omics-100629955","NCT07481396","Molecular Insights Into Post-Cardiac Arrest Brain Injury Via CSF Multi-Omics","Identification of Novel Molecular Pathophysiological Mechanisms of Secondary Brain Injury in Post-cardiac Arrest Syndrome Patients Using Cerebrospinal Fluid Multi-omics Analysis","PCABI-OMICS","Inclusion Criteria:\n\n* Patients receiving post-resuscitation care after out-of-hospital cardiac arrest for secondary brain injury treatment.\n* Patients without contraindications for lumbar puncture catheter insertion for cerebrospinal fluid (CSF) collection. This includes the absence of:\n* Uncontrolled diabetes.Coagulation disorders.\n* Thrombocytopenia (platelet count $\\\u003C 100,000).\n* A history of cirrhosis diagnosis.\n* Current receipt of low molecular weight heparin.\n* Current use of platelet inhibitors.\n* A history of posterior spinal fusion that may interfere with catheter insertion.\n* Local skin infection or rash at the puncture site.\n* Signs of systemic infection or sepsis.\n* A history of lumbar puncture within the past 6 hours.\n\nExclusion Criteria:\n\n* Cerebral Edema: Patients with evidence of cerebral edema on a brain computed tomography (CT) scan performed immediately after spontaneous circulation recovery.\n* Patients who underwent extracorporeal membrane oxygenation (ECMO).\n* Patients who could not maintain integrated therapy for more than 24 hours after cardiac arrest.\n* Patients with a history of acute or chronic brain disease.",{"count":138,"type":20},60,"3 Months","The goal of this study is to uncover the molecular mechanisms responsible for secondary brain injury in patients with post-cardiac arrest syndrome by analyzing cerebrospinal fluid (CSF) using multi-omics techniques.\n\nThe main question this study aims to answer is:\n\nWhich genome-, transcriptome-, proteome-, and metabolome-level changes in CSF are associated with secondary brain injury after cardiac arrest?\n\nTo address this question, CSF samples collected from post-cardiac arrest patients will undergo multi-omics analyses. Identified molecular pathways will be used to screen existing drug databases and generate new therapeutic candidates through computational modeling and compound synthesis. These findings will provide the scientific foundation needed to design and implement future preclinical experiments using cardiac arrest animal models.",[142,143,144,145],"Cardiac Arrest (CA)","Cerebrospinal Fluid","Multiomics","Hypoxic-Ischemic Brain Injury","2026-03-16",{"date":99,"type":36},{"date":149,"type":36},"2025-12-01",{"date":151,"type":20},"2028-02-28",{"name":42,"class":43},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":160,"targetDuration":161,"studyType":57,"phases":4,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":77},"100576260","drug-response-testing-and-repurposing-using-glioblastoma-organoid-100576260","NCT06782984","Drug Response Testing and Repurposing Using Glioblastoma Organoid","Patient-derived Organoids As Predictive Models for Drug Response Testing and Repurporsing in Glioblastoma Therapy","Inclusion Criteria:\n\n* primary or recurrent glioblastoma\n* patients treated with standard treatment including surgery and temozolomide based chemoradiation therapy\n* sufficient tumor sample is available for organoid culture\n\nExclusion Criteria:\n\n* patients who are not underwent concurrent chemoradiation therapy (CCRT) following surgery\n* failed to obtain MRI scan after CCRT\n* patients refusal",{"count":19,"type":20},"1 Year","The aim of this observational study, based on a prospectively collected cohort, is to evaluate the prognostic value of patient-derived organoids in predicting responses to conventional and repurposing drugs, including temozolomide, in patients with primary or recurrent glioblastoma. The primary question is whether the patient's response to temozolomide is recapitulated in their corresponding patient-derived glioblastoma organoid (GBO). Patient drug responses are evaluated using survival data, while GBO drug responses are assessed through a drug-response testing platform utilizing cell viability assays. Additionally, this platform is used to explore the potential application of various chemotherapeutic agents.",[164,165],"Glioblastoma","Organoid",[167,168,169,170],"organoid","glioblastoma","GBO","drug-screening","2025-01-14",{"date":173,"type":36},"2025-01-20",{"date":175,"type":36},"2021-08-18",{"date":177,"type":20},"2030-12",{"name":42,"class":43},""]